Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
7.45
-0.33 (-4.24%)
Aug 6, 2026, 12:28 PM EDT - Market open
Agenus Revenue
Agenus had revenue of $33.74M in the quarter ending March 31, 2026, with 40.18% growth. This brings the company's revenue in the last twelve months to $123.87M, up 24.46% year-over-year. In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth.
Revenue (ttm)
$123.87M
Revenue Growth
+24.46%
P/S Ratio
2.69
Revenue / Employee
$1,529,210
Employees
81
Market Cap
333.40M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Clinuvel Pharmaceuticals | 64.24M |
| Fennec Pharmaceuticals | 51.00M |
| Zentalis Pharmaceuticals | 26.87M |
| Upstream Bio | 3.32M |
| Compass Therapeutics | 850.00K |
| Vicore Pharma Holding AB | 370.61K |
| Lyell Immunopharma | 31.00K |
AGEN News
- 3 hours ago - Agenus Earnings release: Q2 2026 - Filings
- 4 hours ago - Agenus concentrates resources on ROBBIN, discontinues commitment to BATTMAN - TheFly
- 4 hours ago - Agenus reports Q2 revenue $34.5M vs $25.7M last year - TheFly
- 5 hours ago - Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer - Business Wire
- 7 days ago - Agenus Slides: Corporate presentation - Filings
- 7 days ago - Agenus price target raised to $14 from $8 at B. Riley - TheFly
- 8 days ago - Agenus to Provide Second Quarter 2026 Financial Report and Development Update - Business Wire
- 17 days ago - Agenus Registration statement: Registration filing - Filings